Exagen (NASDAQ:XGN) Stock: Insider Jorey Chernett Buys 7,085 Shares

November 11, 2026 by InsiderTrades.com

Key Points

Major shareholder Jorey Chernett bought 7,085 Exagen shares at $5.26 each, a $37,267 purchase that increased his holdings to about 2.63 million shares. His recent Nov. 9–10 purchases exceeded his Nov. 6 sale by 4,320 shares.
Third-quarter revenue rose 7% year over year to $18.42 million, slightly beating estimates, but Exagen’s loss of $0.25 per share was wider than analysts expected. The company reaffirmed 2026 revenue guidance of $72 million to $75 million.
Analysts’ average rating is “Moderate Buy,” with a consensus price target of $10.12; the stock opened at $5.26 after the reported transaction.

Exagen Inc. (NASDAQ:XGN - Get Free Report) major shareholder Jorey Chernett acquired 7,085 shares of the company's stock in a transaction dated Tuesday, November 10th. The shares were bought at an average price of $5.26 per share, for a total transaction of $37,267.10. Following the purchase, the insider owned 2,625,625 shares in the company, valued at approximately $13,810,787.50. This represents a 0.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The shares were sold at an average price of $6.14, for a total value of $69,167.10.
On Monday, November 9th, Jorey Chernett bought 8,500 shares of Exagen stock. The stock was purchased at an average cost of $6.35 per share, with a total value of $53,975.00.
On Monday, October 19th, Jorey Chernett bought 14,000 shares of Exagen stock. The shares were purchased at an average price of $7.46 per share, for a total transaction of $104,440.00.

Exagen Price Performance

NASDAQ XGN opened at $5.26 on Wednesday. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 1.96. The firm's fifty day moving average price is $7.88 and its two-hundred day moving average price is $5.13. Exagen Inc. has a 1 year low of $2.59 and a 1 year high of $9.73.

Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). Exagen had a negative net margin of 26.61% and a negative return on equity of 104.46%. The firm had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.34 million. Equities research analysts expect that Exagen Inc. will post -0.69 earnings per share for the current year.

Key Headlines Impacting Exagen

Here are the key news stories impacting Exagen this week:

Positive Sentiment: Third-quarter revenue rose 7% year over year to $18.4 million, slightly above analysts’ estimates. For the first nine months, revenue grew 11%, net loss narrowed 12%, and adjusted EBITDA loss improved more than 30%. Exagen third-quarter results
Positive Sentiment: Major shareholder Jorey Chernett’s reported purchases on Nov. 9 and 10 exceeded his Nov. 6 sale by 4,320 shares overall, a modest signal of confidence. Exagen also reiterated its 2026 revenue outlook of $72 million to $75 million and expects to launch its myositis offering in early 2027.
Neutral Sentiment: Revenue guidance includes the analyst consensus estimate of $73.9 million, making the reaffirmation broadly in line with expectations rather than a clear forecast upgrade.
Negative Sentiment: Exagen reported a loss of $0.25 per share, wider than estimates of about $0.18–$0.19. Operating expenses increased, widening the quarterly operating loss to $4.4 million from $3.1 million a year earlier; quarterly adjusted EBITDA loss also edged wider. Cash was $28.1 million, down from $35.7 million a year earlier. These results raise concerns about near-term profitability and cash use despite sales growth.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP bought a new position in Exagen in the 2nd quarter valued at about $998,000. Flputnam Investment Management Co. bought a new stake in shares of Exagen during the second quarter worth approximately $1,343,000. Man Group plc bought a new stake in shares of Exagen during the second quarter worth approximately $778,000. BlackRock Inc. acquired a new position in shares of Exagen in the second quarter valued at approximately $663,000. Finally, FourWorld Capital Management LLC increased its stake in shares of Exagen by 61.2% during the first quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company's stock worth $1,320,000 after purchasing an additional 166,950 shares during the period. Institutional investors and hedge funds own 75.25% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on XGN shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of Exagen in a report on Wednesday, November 4th. BTIG Research raised their price objective on Exagen from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. B. Riley Financial initiated coverage on Exagen in a research report on Friday, September 11th. They issued a "buy" rating and a $12.00 price objective for the company. TD Cowen boosted their target price on Exagen from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, October 13th. Finally, Canaccord Genuity Group increased their price target on Exagen from $9.00 to $11.00 and gave the company a "buy" rating in a research note on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Exagen presently has an average rating of "Moderate Buy" and a consensus price target of $10.12.

Read Our Latest Research Report on XGN

About Exagen

(Get Free Report)

Exagen Inc. is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time. Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.